These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38939955)

  • 1. Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients.
    Crotti L; Neves R; Dagradi F; Musu G; Giannetti F; Bos JM; Barbieri M; Cerea P; Giovenzana FLF; Torchio M; Mura M; Gnecchi M; Conte G; Auricchio A; Sala L; Odening KE; Ackerman MJ; Schwartz PJ
    Circulation; 2024 Aug; 150(7):531-543. PubMed ID: 38939955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
    Bos JM; Crotti L; Rohatgi RK; Castelletti S; Dagradi F; Schwartz PJ; Ackerman MJ
    Circ Arrhythm Electrophysiol; 2019 May; 12(5):e007280. PubMed ID: 31006312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biology of the long QT syndrome: impact on management.
    Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
    Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
    O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
    Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
    Matsa E; Rajamohan D; Dick E; Young L; Mellor I; Staniforth A; Denning C
    Eur Heart J; 2011 Apr; 32(8):952-62. PubMed ID: 21367833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model.
    Mehta A; Ramachandra CJA; Singh P; Chitre A; Lua CH; Mura M; Crotti L; Wong P; Schwartz PJ; Gnecchi M; Shim W
    Eur Heart J; 2018 Apr; 39(16):1446-1455. PubMed ID: 29020304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
    Schwartz PJ; Priori SG; Locati EH; Napolitano C; Cantù F; Towbin JA; Keating MT; Hammoude H; Brown AM; Chen LS; Colatsky TJ
    Circulation; 1995 Dec; 92(12):3381-6. PubMed ID: 8521555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2.
    Giannetti F; Barbieri M; Shiti A; Casini S; Sager PT; Das S; Pradhananga S; Srinivasan D; Nimani S; Alerni N; Louradour J; Mura M; Gnecchi M; Brink P; Zehender M; Koren G; Zaza A; Crotti L; Wilde AAM; Schwartz PJ; Remme CA; Gepstein L; Sala L; Odening KE
    Europace; 2023 May; 25(5):. PubMed ID: 37099628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
    Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
    J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.
    Paci M; Passini E; Severi S; Hyttinen J; Rodriguez B
    Heart Rhythm; 2017 Nov; 14(11):1704-1712. PubMed ID: 28756098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Advantages, Challenges, and Future of Human-Induced Pluripotent Stem Cell Lines in Type 2 Long QT Syndrome.
    Cai D; Zheng Z; Jin X; Fu Y; Cen L; Ye J; Song Y; Lian J
    J Cardiovasc Transl Res; 2023 Feb; 16(1):209-220. PubMed ID: 35976484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
    Terrenoire C; Wang K; Tung KW; Chung WK; Pass RH; Lu JT; Jean JC; Omari A; Sampson KJ; Kotton DN; Keller G; Kass RS
    J Gen Physiol; 2013 Jan; 141(1):61-72. PubMed ID: 23277474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
    Shimizu W; Antzelevitch C
    Circulation; 1997 Sep; 96(6):2038-47. PubMed ID: 9323097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression and Replacement Gene Therapy for
    Bains S; Zhou W; Dotzler SM; Martinez K; Kim CJ; Tester DJ; Ye D; Ackerman MJ
    Circ Genom Precis Med; 2022 Dec; 15(6):e003719. PubMed ID: 36252106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
    Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
    Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.
    Lahti AL; Kujala VJ; Chapman H; Koivisto AP; Pekkanen-Mattila M; Kerkelä E; Hyttinen J; Kontula K; Swan H; Conklin BR; Yamanaka S; Silvennoinen O; Aalto-Setälä K
    Dis Model Mech; 2012 Mar; 5(2):220-30. PubMed ID: 22052944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients With Long-QT Syndrome Caused by Impaired
    Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
    Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
    Priori SG; Cantù F; Schwartz PJ
    Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docosahexaenoic acid normalizes QT interval in long QT type 2 transgenic rabbit models in a genotype-specific fashion.
    Castiglione A; Hornyik T; Wülfers EM; Giammarino L; Edler I; Jowais JJ; Rieder M; Perez-Feliz S; Koren G; Bősze Z; Varró A; Zehender M; Brunner M; Bode C; Liin SI; Larsson HP; Baczkó I; Odening KE
    Europace; 2022 Mar; 24(3):511-522. PubMed ID: 34601592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatial correlation of action potential duration and diastolic dysfunction in transgenic and drug-induced LQT2 rabbits.
    Odening KE; Jung BA; Lang CN; Cabrera Lozoya R; Ziupa D; Menza M; Relan J; Franke G; Perez Feliz S; Koren G; Zehender M; Bode C; Brunner M; Sermesant M; Föll D
    Heart Rhythm; 2013 Oct; 10(10):1533-41. PubMed ID: 23892340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.